The application of repetitive transcranial magnetic stimulation (rTMS) as a treatment for Major Depressive Disorder (MDD) has been shown to be effective when applied to either the right or left… Click to show full abstract
The application of repetitive transcranial magnetic stimulation (rTMS) as a treatment for Major Depressive Disorder (MDD) has been shown to be effective when applied to either the right or left dorsolateral prefrontal cortex (DLPFC) in placebo controlled studies [1,2] as well as open-label studies [3]. Given the effectiveness of rTMS as a treatment forMDD, the interest for finding clinical or (neuro)physiological predictors has been increasing. In 2012, we [4] reported neurophysiological predictors of non-response (NR) for rTMS treatment in MDD. These predictors included the EEG metrics: increased fronto-central theta, a low individual alpha peak frequency (iAPF), and a large P300 amplitude at site location Pz in a sample of 90 MDD patients, however these biomarkers still require replication. The aim of the current study is to investigate the replicability of these findings in a newly collected sample, and also to make our EEG and ERP data available to scientific use for replication analyses that have specific formulated hypotheses, and thus facilitating future replication studies.
               
Click one of the above tabs to view related content.